ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
A New Promoter Allows Optogenetic Vision Restoration with Enhanced Sensitivity in Macaque Retina.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Retinal Viral Gene Therapy: Impact of Route of Administration on Serious Adverse Events-A Systematic Review.Clinical & experimental ophthalmology · 2025Pooled it
- A Systematic Review of Optogenetic Vision Restoration: History, Challenges, and New Inventions from Bench to Bedside.Cold Spring Harbor perspectives in medicine · 2023Pooled it
- Trends in neuroprosthetic technologies to restore sensations.Biomedical engineering letters · 2026Review
- Optogenetics for Investigating and Targeting Hallmark Traits of Cancer.Biomolecules · 2026Review
- Evaluation of Lipid Nanoparticles as Vehicles for Optogenetic Delivery in Primary Cortical Neurons.Pharmaceutics · 2025Article
- Inner Limiting Membrane Peel Extends In Vivo Calcium Imaging of Retinal Ganglion Cell Activity Beyond the Fovea in Non-Human Primate.Investigative ophthalmology & visual science · 2025Article
- SIRT1-based therapy targets a gene program involved in mitochondrial turnover in a model of retinal neurodegeneration.Scientific reports · 2025Article
- Reactivating the phototransduction cascade with a mutation agnostic gene therapy preserves vision in rod-cone dystrophies.iScience · 2025Article
- Evolution of Light-Sensitive Proteins in Optogenetic Approaches for Vision Restoration: A Comprehensive Review.Biomedicines · 2025Review
- Intravitreal AAV2 gene delivery to feline retinal ganglion cells.Vision research · 2025Article
- Optogenetic Stimulation Recruits Cortical Neurons in a Morphology-Dependent Manner.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Gene therapy for glaucoma: Targeting key mechanisms.Vision research · 2024Review
- AAV dose-dependent transduction efficiency in retinal ganglion cells and functional efficacy of optogenetic vision restoration.Gene therapy · 2024Article
- Comparison of SNCG and NEFH Promoter-Driven Expression of Human SIRT1 Expression in a Mouse Model of Glaucoma.Translational vision science & technology · 2024Article
- Optogenetic Vision Restoration.Cold Spring Harbor perspectives in medicine · 2024Review
- Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives.Journal of clinical medicine · 2024Review
- Theoretical prediction of broadband ambient light optogenetic vision restoration with ChRmine and its mutants.Scientific reports · 2024Article
- AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes.Gene therapy · 2024Article
- Optogenetic targeting of AII amacrine cells restores retinal computations performed by the inner retina.Molecular therapy. Methods & clinical development · 2023Article
- Emerging optogenetics technologies in biomedical applications.Smart medicine · 2023Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 2 countries.
Antoine ChaffiolINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Romain CapletteINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Céline JaillardINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Elena BrazhnikovaINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Mélissa DesrosiersINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Elisabeth DubusINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Laëtitia DuhamelINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Emilie MacéINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Olivier MarreINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France.
Patrick BenoitSanofi Ophthalmology Unit, 17 rue Moreau, 75012 Paris, France.
Philippe HantrayeDépartement des Sciences du Vivant (DSV), MIRCen, Institut d'Imagerie Biomédicale (I2BM), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses 92260, France; Neurodegenerative Diseases Laboratory, CNRS UMR9199, Université Paris-Sud, Université Paris-Saclay, Fontenay-aux-Roses 92260, France.
Alexis-Pierre BemelmansDépartement des Sciences du Vivant (DSV), MIRCen, Institut d'Imagerie Biomédicale (I2BM), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses 92260, France; Neurodegenerative Diseases Laboratory, CNRS UMR9199, Université Paris-Sud, Université Paris-Saclay, Fontenay-aux-Roses 92260, France.
Ernst BambergDepartment of Biophysical Chemistry, Max Planck Institute of Biophysics, 60438 Frankfurt am Main, Germany.
Jens DuebelINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France. Electronic address: jens.duebel@gmail.com.
José-Alain SahelINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France; CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC, 28 rue de Charenton, 75012 Paris, France; Fondation Ophtalmologique Adolphe de Rothschild, 75019 Paris, France. Electronic address: j.sahel@gmail.com.
Serge PicaudINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France. Electronic address: serge.picaud@inserm.fr.
Deniz DalkaraINSERM U968, Institut de la Vision, 75012 Paris, France; UMRS968, Institut de la Vision, Sorbonne Universités, Pierre et Marie Curie University (UPMC) University Paris 06, 75012 Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR7210, Institut de la Vision, 75012 Paris, France. Electronic address: deniz.dalkara@gmail.com.
Inserm · FRSorbonne Université · FRInstitut de la Vision · FRCentre National de la Recherche Scientifique · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut d'Imagerie Biomédicale · FRMax Planck Institute of Biophysics · DESanofi (France) · FR
Funding
Three Dimensional Holography for Parallel Multi-target Optogenetic Circuit ManipulationU01NS090501 · NINDS · PIERRE AND MARIE CURIE UNIVERSITY · PI EMILIANI, VALENTINA, PICAUD, SERGE · 2014 to 2016
$941kNINDS NIH HHS U01 NS090501
Abstract
The majority of inherited retinal degenerations converge on the phenotype of photoreceptor cell death. Second- and third-order neurons are spared in these diseases, making it possible to restore retinal light responses using optogenetics. Viral expression of channelrhodopsin in the third-order neurons under ubiquitous promoters was previously shown to restore visual function, albeit at light intensities above illumination safety thresholds. Here, we report (to our knowledge, for the first time) activation of macaque retinas, up to 6 months post-injection, using channelrhodopsin-Ca
Indexed as
Promoter Regions, GeneticRecovery of FunctionAnimalsChannelrhodopsinsDependovirusDisease Models, AnimalGene ExpressionGenetic TherapyGenetic VectorsIntravitreal InjectionsLightMacaca fascicularisMiceMice, Inbred C57BLMice, TransgenicOptogeneticsChannelrhodopsinsAAVoptogeneticsretinal gene therapyretinitis pigmentosavisual restoration
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.